Report cover image

Europe Cancer Immunotherapy Market - Industry Trends and Forecast to 2033

Publisher Data Bridge Market Research
Published Dec 01, 2023
Length 348 Pages
SKU # DAABD18458898

Description

Europe Cancer Immunotherapy Market - Industry Trends and Forecast to 2033


The Europe cancer immunotherapy market is expected to reach USD 49,512.88 million by 2031 from USD 18,921.43 million in 2023, growing at a CAGR of 13.7% during the forecast period of 2024 to 2031.
Market Segmentation
Europe Cancer Immunotherapy Market, By Product Type (Checkpoint Inhibitors, Monoclonal Antibodies, Vaccines, Cell Therapies, Immunomodulators, and Oncolytic Virus), Application (Lung Cancer, Breast Cancer, Melanoma, Myeloma, Prostate Cancer, Ovarian Cancer, Cervical Cancer, Stomach Cancer, Colorectal Cancer, Head & Neck Cancer, and Others), End User (Hospitals, Oncology Clinics, Homecare, and Others), Form (Intravenous (IV), Intramuscular, and Oral), Distribution Channel (Direct Tenders, Retail Sales, and Pharmacies), Country (Germany, France, U.K., Italy, Russia, Spain, Turkey, Belgium, Netherlands, Switzerland, Denmark, and Rest of Europe) - Industry Trends and Forecast to 2031

Overview of Europe Cancer Immunotherapy Market Dynamics

Driver
• Rising prevalence of cancer incidences

Restrain

• Increasing occurrence of immune-related adverse events

Opportunity

• Growing trend towards combination therapies

Market Players

Some of the major market players operating in the Europe cancer immunotherapy market are:

• Merck & Co., Inc.
• F. Hoffmann-La Roche Ltd
• Bristol-Myers Squibb Company
• Janssen Pharmaceutical
• AstraZeneca
• Gilead Sciences, Inc.
• Eli Lilly and Company
• Amgen Inc.
• Novartis AG
• GSK
• Pfizer Inc.
• Incyte

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.

Please note: This publisher does offer titles that are created upon receipt of order. The report will take approximately 15-20 business days to prepare and deliver.

Table of Contents

348 Pages
1 Introduction
1.1 Objectives Of The Study
1.2 Market Definition
1.3 Overview Of The Europe Cancer Immunotherapy Market
1.4 Currency And Pricing
1.5 Limitations
1.6 Markets Covered
2 Market Segmentation
2.1 Markets Covered
2.2 Geographical Scope
2.3 Years Considered For The Study
2.4 Dbmr Tripod Data Validation Model
2.5 Primary Interviews With Key Opinion Leaders
2.6 Multivariate Modelling
2.7 Product Type Segment Lifeline Curve
2.8 Market End User Coverage Grid
2.9 Dbmr Market Position Grid
2.10 Vendor Share Analysis
2.11 Secondary Sources
2.12 Assumptions
3 Executive Summary
4 Premium Insights
4.1 Pestal Analysis
4.2 Porters 5 Forces
5 Europe Cancer Immunotherapy Market: Regulations
6 Market Overview
6.1 Drivers
6.1.1 Rising Prevalence Of Cancer Incidences
6.1.2 Rising Technological Advancements
6.1.3 Increased Understanding Of Tumor Microenvironment
6.1.4 Rise In Patient Awareness And Demand For Targeted Treatment
6.2 Restraints
6.2.1 Increasing Occurrence Of Immune-related Adverse Events
6.2.2 Developing Resistance To Cancer Treatment
6.3 Opportunities
6.3.1 Growing Trend Towards Combination Therapies
6.3.2 Rising Integration Of Artificial Intelligence And Digital Health Tools
6.3.3 Development Of Next-generation Immunotherapies
6.4 Challenges
6.4.1 Lack Of Standardization In Biomarker Testing
6.4.2 Complexity Of Developing And Implementing Personalized Medicine
7 Europe Cancer Immunotherapy Market , By Product Type
7.1 Overview
7.2 Checkpoint Inhibitors
7.2.1 Programmed Death 1 (Pd-1) & Programmed Death Ligand 1 (Pd-l1)
7.2.2 Cytotoxic T-lymphocyte-associated Protein-4 (Ctla-4)
7.3 Monoclonal Antibodies
7.3.1 Naked Monoclonal Antibodies
7.3.2 Conjugated Monoclonal Antibodies
7.3.3 Bispecific Monoclonal Antibodies
7.4 Vaccines
7.4.1 Prophylactic Vaccines
7.4.2 Therapeutic Vaccines
7.5 Cell Therapies
7.5.1 Chimeric Antigen Receptor (Car) T Cell Therapy
7.5.2 T Cell Therapy
7.6 Immunomodulators
7.6.1 Interferons
7.6.2 Interleukins
7.6.3 Granulocyte-macrophage Colony-stimulating Factor
7.7 Oncolytic Virus
8 Europe Cancer Immunotherapy Market , By End User
8.1 Overview
8.2 Hospitals
8.3 Oncology Clinics
8.4 Homecare
8.5 Others
9 Europe Cancer Immunotherapy Market, By Distribution Channel
9.1 Overview
9.2 Direct Tenders
9.3 Retail Sales
9.4 Pharmacies
9.4.1 Hospital
9.4.2 Retail
9.4.3 Online
10 Europe Cancer Immunotherapy Market, By Form
10.1 Overview
10.2 Intravenous (Iv)
10.3 Intramuscular
10.4 Oral
11 Europe Cancer Immunotherapy Market, By Application
11.1 Overview
11.2 Lung Cancer
11.2.1 Checkpoint Inhibitors
11.2.2 Monoclonal Antibodies
11.2.3 Cell Therapies
11.2.4 Immunomodulators
11.3 Breast Cancer
11.3.1 Checkpoint Inhibitors
11.3.2 Monoclonal Antibodies
11.3.3 Cell Therapies
11.3.4 Immunomodulators
11.4 Melanoma
11.4.1 Checkpoint Inhibitors
11.4.2 Monoclonal Antibodies
11.4.3 Cell Therapies
11.4.4 Immunomodulators
11.4.5 Oncolytic Virus
11.5 Multiple Myeloma
11.5.1 Checkpoint Inhibitors
11.5.2 Monoclonal Antibodies
11.5.3 Cell Therapies
11.5.4 Immunomodulators
11.6 Prostate Cancer
11.6.1 Checkpoint Inhibitors
11.6.2 Monoclonal Antibodies
11.6.3 Cell Therapies
11.6.4 Immunomodulators
11.6.5 Vaccines
11.7 Ovarian Cancer
11.7.1 Checkpoint Inhibitors
11.7.2 Monoclonal Antibodies
11.7.3 Cell Therapies
11.7.4 Immunomodulators
11.8 Cervical Cancer
11.8.1 Checkpoint Inhibitors
11.8.2 Monoclonal Antibodies
11.8.3 Vaccines
11.8.4 Cell Therapies
11.8.5 Immunomodulators
11.9 Stomach Cancer
11.9.1 Checkpoint Inhibitors
11.9.2 Monoclonal Antibodies
11.9.3 Cell Therapies
11.9.4 Immunomodulators
11.10 Colorectal Cancer
11.10.1 Checkpoint Inhibitors
11.10.2 Monoclonal Antibodies
11.10.3 Cell Therapies
11.10.4 Immunomodulators
11.11 Head And Neck Cancer
11.11.1 Checkpoint Inhibitors
11.11.2 Monoclonal Antibodies
11.11.3 Cell Therapies
11.11.4 Immunomodulators
11.12 Others
11.12.1 Checkpoint Inhibitors
11.12.2 Monoclonal Antibodies
11.12.3 Vaccines
11.12.4 Cell Therapies
11.12.5 Immunomodulators
12 Europe Cancer Immunotherapy Market, By Region
12.1 Europe
12.1.1 Germany
12.1.2 France
12.1.3 Italy
12.1.4 Spain
12.1.5 U.K.
12.1.6 Switzerland
12.1.7 Netherlands
12.1.8 Russia
12.1.9 Turkey
12.1.10 Poland
12.1.11 Hungary
12.1.12 Lithuania
12.1.13 Austria
12.1.14 Ireland
12.1.15 Norway
12.1.16 Rest Of Europe
13 Europe Cancer Immunotherapy Market, Company Landscape
13.1 Company Share Analysis: Europe
14 Swot Analysis
15 Company Profiles
15.1 Merck & Co., Inc.
15.1.1 Company Snapshot
15.1.2 Revenue Analysis
15.1.3 Company Share Analysis
15.1.4 Product Portfolio
15.1.5 Recent Developments
15.2 F. Hoffmann-la Roche Ltd
15.2.1 Company Snapshot
15.2.2 Revenue Analysis
15.2.3 Company Share Analysis
15.2.4 Product Portfolio
15.2.5 Recent Developments
15.3 Bristol-myers Squibb Company
15.3.1 Company Snapshot
15.3.2 Revenue Analysis
15.3.3 Company Share Analysis
15.3.4 Product Portfolio
15.3.5 Recent Developments
15.4 Janssen Europe Services, Llc
15.4.1 Company Snapshot
15.4.2 Revenue Analysis
15.4.3 Company Share Analysis
15.4.4 Product Portfolio
15.4.5 Recent Developments
15.5 Astrazeneca
15.5.1 Company Snapshot
15.5.2 Revenue Analysis
15.5.3 Company Share Analysis
15.5.4 Product Portfolio
15.5.5 Recent Developments
15.6 Abbvie Inc.
15.6.1 Company Snapshot
15.6.2 Pipeline Portfolio
15.6.3 Recent Developments
15.7 Amgen Inc.
15.7.1 Company Snapshot
15.7.2 Revenue Analysis
15.7.3 Pipeline Portfolio
15.7.4 Product Portfolio
15.7.5 Recent Developments
15.8 Atara Biotherapeutics, Inc.
15.8.1 Company Snapshot
15.8.2 Pipeline Portfolio
15.8.3 Recent Developments
15.9 Bayer Ag
15.9.1 Company Snapshot
15.9.2 Pipeline Portfolio
15.9.3 Recent Developments
15.10 Celldex Therapeutics.
15.10.1 Company Snapshot
15.10.2 Pipeline Portfolio
15.10.3 Recent Developments
15.11 Cellectis
15.11.1 Company Snapshot
15.11.2 Pipeline Portfolio
15.11.3 Recent Developments
15.12 Gilead Sciences, Inc.
15.12.1 Company Snapshot
15.12.2 Revenue Analysis
15.12.3 Product Portfolio
15.12.4 Recent Developments
15.13 Gsk Plc.
15.13.1 Company Snapshot
15.13.2 Revenue Analysis
15.13.3 Product Portfolio
15.13.4 Recent Developments
15.14 Incyte.
15.14.1 Company Snapshot
15.14.2 Revenue Analysis
15.14.3 Product Portfolio
15.14.4 Recent Developments
15.15 Lilly.
15.15.1 Company Snapshot
15.15.2 Revenue Analysis
15.15.3 Product Portfolio
15.15.4 Recent Developments
15.16 Novartis Ag
15.16.1 Company Snapshot
15.16.2 Revenue Analysis
15.16.3 Pipeline Portfolio
15.16.4 Product Portfolio
15.16.5 Recent Developments
15.17 Pfizer Inc.
15.17.1 Company Snapshot
15.17.2 Revenue Analysis
15.17.3 Product Portfolio
15.17.4 Recent Developments
16 Questionnaire
17 Related Reports
List Of Tables
Table 1 Europe Cancer Immunotherapy Market , By Product Type, 2022- 2031 (Usd Million)
Table 2 Europe Checkpoint Inhibitors Cancer Immunotherapy In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 3 Europe Checkpoint Inhibitors In Cancer Immunotherapy Market , By Type, 2022- 2031 (Usd Million)
Table 4 Europe Checkpoint Inhibitors In Cancer Immunotherapy Market , By Type, 2022- 2031 (Units)
Table 5 Europe Monoclonal Antibodies In Cancer Immunotherapy In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 6 Europe Monoclonal Antibodies In Cancer Immunotherapy Market , By Type, 2022- 2031 (Usd Million)
Table 7 Europe Monoclonal Antibodies In Cancer Immunotherapy Market , By Type, 2022- 2031 (Units)
Table 8 Europe Vaccines In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 9 Europe Vaccines In Cancer Immunotherapy Market , By Type, 2022- 2031 (Usd Million)
Table 10 Europe Vaccines In Cancer Immunotherapy Market , By Type, 2022- 2031 (Units)
Table 11 Europe Cell Therapies In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 12 Europe Cell Therapies In Cancer Immunotherapy Market , By Type, 2022- 2031 (Usd Million)
Table 13 Europe Cell Therapies In Cancer Immunotherapy Market , By Type, 2022- 2031 (Units)
Table 14 Europe Immunomodulators In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 15 Europe Immunomodulators In Cancer Immunotherapy Market , By Type, 2022- 2031 (Usd Million)
Table 16 Europe Immunomodulators In Cancer Immunotherapy Market, By Type, 2022-2031 (Units)
Table 17 Europe Oncolytic Virus In Cancer Immunotherapymarket, By Region, 2022-2031 (Usd Million)
Table 18 Europe Cancer Immunotherapy Market , By End User, 2022- 2031 (Usd Million)
Table 19 Europe Hospitals In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 20 Europe Oncology Clinics In Cancer Immunotherapy In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 21 Europe Homecare In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 22 Europe Others In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 23 Europe Cancer Immunotherapy Market, By Distribution Channel, 2022-2031 (Usd Million)
Table 24 Europe Direct Tenders In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 25 Europe Retail Sales In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 26 Europe Pharmacies In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 27 Europe Pharmacies In Cancer Immunotherapy Market, By Distribution Channel, 2022-2031 (Usd Million)
Table 28 Europe Cancer Immunotherapy Market, By Form, 2022-2031 (Usd Million)
Table 29 Europe Intravenous In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 30 Europe Intramuscular In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 31 Europe Oral In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 32 Europe Cancer Immunotherapy Market, By Application, 2022-2031 (Usd Million)
Table 33 Europe Lung Canceri N Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 34 Europe Lung Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 35 Europe Breast Canceri N Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 36 Europe Breast Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 37 Europe Melanoma In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 38 Europe Melanoma Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 39 Europe Multiple Myeloma In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 40 Europe Multiple Myeloma Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 41 Europe Prostate Cancer In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 42 Europe Prostate Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 43 Europe Ovarianc Ancer In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 44 Europe Ovarian Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 45 Europe Cervical Cancer In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 46 Europe Cervical Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 47 Europe Stomach Cancer In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 48 Europe Stomach Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 49 Europe Colorectal Cancer In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 50 Europe Colorectal Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 51 Europe Head And Neck Cancer In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 52 Europe Head & Neck Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 53 Europe Others In Cancer Immunotherapy Market, By Region, 2022-2031 (Usd Million)
Table 54 Europe Others Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 55 Europe Cancer Immunotherapy Market, By Country, 2022-2031 (Usd Million)
Table 56 Europe Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 57 Europe Checkpoint Inhibitors In Cancer Immunotherapy Market, By Type, 2022-2031 (Usd Million)
Table 58 Europe Checkpoint Inhibitors In Cancer Immunotherapy Market, By Type, 2022-2031 (Units)
Table 59 Europe Monoclonal Antibodies In Cancer Immunotherapy Market, By Type, 2022-2031 (Usd Million)
Table 60 Europe Monoclonal Antibodies In Cancer Immunotherapy Market, By Type, 2022-2031 (Units)
Table 61 Europe Vaccines In Cancer Immunotherapy Market, By Type, 2022-2031 (Usd Million)
Table 62 Europe Vaccines In Cancer Immunotherapy Market, By Type, 2022-2031 (Units)
Table 63 Europe Cell Therapies In Cancer Immunotherapy Market, By Type, 2022-2031 (Usd Million)
Table 64 Europe Cell Therapies In Cancer Immunotherapy Market, By Type, 2022-2031 (Units)
Table 65 Europe Immunomodulators In Cancer Immunotherapy Market, By Type, 2022-2031 (Usd Million)
Table 66 Europe Immunomodulators In Cancer Immunotherapy Market, By Type, 2022-2031 (Units)
Table 67 Europe Cancer Immunotherapy Market, By Application, 2022-2031 (Usd Million)
Table 68 Europe Lung Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 69 Europe Breast Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 70 Europe Melanoma In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 71 Europe Multiple Myeloma In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 72 Europe Prostate Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 73 Europe Ovarian Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 74 Europe Cervical Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 75 Europe Stomach Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 76 Europe Colorectal Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 77 Europe Head And Neck Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 78 Europe Others In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 79 Europe Cancer Immunotherapy Market, By End User, 2022-2031 (Usd Million)
Table 80 Europe Cancer Immunotherapy Market, By Form, 2022-2031 (Usd Million)
Table 81 Europe Cancer Immunotherapy Market, By Distribution Channel, 2022-2031 (Usd Million)
Table 82 Europe Pharmacies In Cancer Immunotherapy Market, By Distribution Channel, 2022-2031 (Usd Million)
Table 83 Germany Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 84 Germany Checkpoint Inhibitors In Cancer Immunotherapy Market, By Type, 2022-2031 (Usd Million)
Table 85 Germany Checkpoint Inhibitors In Cancer Immunotherapy Market, By Type, 2022-2031 (Units)
Table 86 Germany Checkpoint Inhibitors In Cancer Immunotherapy Market, By Type, 2022-2031, (Asp)
Table 87 Germany Monoclonal Antibodies In Cancer Immunotherapy Market, By Type, 2022-2031 (Usd Million)
Table 88 Germany Monoclonal Antibodies In Cancer Immunotherapy Market, By Type, 2022-2031 (Units)
Table 89 Germany Monoclonal Antibodies In Cancer Immunotherapy Market, By Type, 2022-2031, (Asp)
Table 90 Germany Vaccines In Cancer Immunotherapy Market, By Type, 2022-2031 (Usd Million)
Table 91 Germany Vaccines In Cancer Immunotherapy Market, By Type, 2022-2031 (Units)
Table 92 Germany Vaccines In Cancer Immunotherapy Market, By Type, 2022-2031, (Asp)
Table 93 Germany Cell Therapies In Cancer Immunotherapy Market, By Type, 2022-2031 (Usd Million)
Table 94 Germany Cell Therapies In Cancer Immunotherapy Market, By Type, 2022-2031 (Units)
Table 95 Germany Cell Therapies In Cancer Immunotherapy Market, By Type, 2022-2031, (Asp)
Table 96 Germany Immunomodulators In Cancer Immunotherapy Market, By Type, 2022-2031 (Usd Million)
Table 97 Germany Immunomodulators In Cancer Immunotherapy Market, By Type, 2022-2031 (Units)
Table 98 Germany Immunomodulators In Cancer Immunotherapy Market, By Type, 2022-2031, (Asp)
Table 99 Germany Cancer Immunotherapy Market, By Application, 2022-2031 (Usd Million)
Table 100 Germany Lung Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 101 Germany Breast Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 102 Germany Melanoma In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 103 Germany Multiple Myeloma In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 104 Germany Prostate Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 105 Germany Ovarian Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 106 Germany Cervical Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 107 Germany Stomach Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 108 Germany Colorectal Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 109 Germany Head And Neck Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 110 Germany Others In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 111 Germany Cancer Immunotherapy Market, By End User, 2022-2031 (Usd Million)
Table 112 Germany Cancer Immunotherapy Market, By Form, 2022-2031 (Usd Million)
Table 113 Germany Cancer Immunotherapy Market, By Distribution Channel, 2022-2031 (Usd Million)
Table 114 Germany Pharmacies In Cancer Immunotherapy Market, By Distribution Channel, 2022-2031 (Usd Million)
Table 115 France Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 116 France Checkpoint Inhibitors In Cancer Immunotherapy Market, By Type, 2022-2031 (Usd Million)
Table 117 France Checkpoint Inhibitors In Cancer Immunotherapy Market, By Type, 2022-2031 (Units)
Table 118 France Checkpoint Inhibitors In Cancer Immunotherapy Market, By Type, 2022-2031, (Asp)
Table 119 France Monoclonal Antibodies In Cancer Immunotherapy Market, By Type, 2022-2031 (Usd Million)
Table 120 France Monoclonal Antibodies In Cancer Immunotherapy Market, By Type, 2022-2031 (Units)
Table 121 France Monoclonal Antibodies In Cancer Immunotherapy Market, By Type, 2022-2031, (Asp)
Table 122 France Vaccines In Cancer Immunotherapy Market, By Type, 2022-2031 (Usd Million)
Table 123 France Vaccines In Cancer Immunotherapy Market, By Type, 2022-2031 (Units)
Table 124 France Vaccines In Cancer Immunotherapy Market, By Type, 2022-2031, (Asp)
Table 125 France Cell Therapies In Cancer Immunotherapy Market, By Type, 2022-2031 (Usd Million)
Table 126 France Cell Therapies In Cancer Immunotherapy Market, By Type, 2022-2031 (Units)
Table 127 France Cell Therapies In Cancer Immunotherapy Market, By Type, 2022-2031, (Asp)
Table 128 France Immunomodulators In Cancer Immunotherapy Market, By Type, 2022-2031 (Usd Million)
Table 129 France Immunomodulators In Cancer Immunotherapy Market, By Type, 2022-2031 (Units)
Table 130 France Immunomodulators In Cancer Immunotherapy Market, By Type, 2022-2031, (Asp)
Table 131 France Cancer Immunotherapy Market, By Application, 2022-2031 (Usd Million)
Table 132 France Lung Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 133 France Breast Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 134 France Melanoma In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 135 France Multiple Myeloma In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 136 France Prostate Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 137 France Ovarian Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 138 France Cervical Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 139 France Stomach Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 140 France Colorectal Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 141 France Head And Neck Cancer In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 142 France Others In Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 143 France Cancer Immunotherapy Market, By End User, 2022-2031 (Usd Million)
Table 144 France Cancer Immunotherapy Market, By Form, 2022-2031 (Usd Million)
Table 145 France Cancer Immunotherapy Market, By Distribution Channel, 2022-2031 (Usd Million)
Table 146 France Pharmacies In Cancer Immunotherapy Market, By Distribution Channel, 2022-2031 (Usd Million)
Table 147 Italy Cancer Immunotherapy Market, By Product Type, 2022-2031 (Usd Million)
Table 148 Italy Checkpoint Inhibitors In Cancer Immunotherapy Market, By Type, 2022-2031 (Usd Million)
Table 149 Italy Checkpoint Inhibitors In Cancer Immunotherapy Market, By Type, 2022-2031 (Units)
List Of Figures
Figure 1 Europe Cancer Immunotherapy Market: Segmentation
Figure 2 Europe Cancer Immunotherapy Market: Data Triangulation
Figure 3 Europe Cancer Immunotherapy Market: Droc Analysis
Figure 4 Europe Cancer Immunotherapy Market: Europe Vs Regional Market Analysis
Figure 5 Europe Cancer Immunotherapy Market: Company Research Analysis
Figure 6 Europe Cancer Immunotherapy Market: Interview Demographics
Figure 7 Europe Cancer Immunotherapy Market: Market End User Coverage Grid
Figure 8 Europe Cancer Immunotherapy Market: Dbmr Market Position Grid
Figure 9 Europe Cancer Immunotherapy Market: Vendor Share Analysis
Figure 10 Europe Cancer Immunotherapy Market: Segmentation
Figure 11 Rising Prevalence Of Cancer And Rising Technological Advancements Are Expected To Drive The Growth Of The Europe Cancer Immunotherapy Market From 2024 To 2034
Figure 12 Checkpoint Inhibitors Segment Is Expected To Account For The Largest Share Of The Europe Cancer Chemotherapy Consumables Market In 2024 To 2031
Figure 13 Drivers, Restraints, Opportunities, And Challenges Of Europe Cancer Immunotherapy Market
Figure 14 Europe Cancer Immunotherapymarket : By Product Type, 2023
Figure 15 Europe Cancer Immunotherapymarket : By Product Type, 2024-2031 (Usd Million)
Figure 16 Europe Cancer Immunotherapymarket : By Product Type, Cagr (2024-2031)
Figure 17 Europe Cancer Immunotherapymarket : By Product Type, Lifeline Curve
Figure 18 Europe Cancer Immunotherapymarket : By End User, 2023
Figure 19 Europe Cancer Immunotherapymarket : By End User, 2024-2031 (Usd Million)
Figure 20 Europe Cancer Immunotherapymarket : By End User, Cagr (2024-2031)
Figure 21 Europe Cancer Immunotherapymarket : By End User, Lifeline Curve
Figure 22 Europe Cancer Immunotherapy Market: By Distribution Channel, 2023
Figure 23 Europe Cancer Immunotherapy Market: By Distribution Channel, 2024-2031 (Usd Million)
Figure 24 Europe Cancer Immunotherapy Market: By Distribution Channel, Cagr (2024-2031)
Figure 25 Europe Cancer Immunotherapy Market: By Distribution Channel, Lifeline Curve
Figure 26 Europe Cancer Immunotherapy Market: By Form, 2023
Figure 27 Europe Cancer Immunotherapy Market: By Form, 2024-2031 (Usd Million)
Figure 28 Europe Cancer Immunotherapy Market: By Form, Cagr (2024-2031)
Figure 29 Europe Cancer Immunotherapy Market: By Form, Lifeline Curve
Figure 30 Europe Cancer Immunotherapy Market: By Application, 2023
Figure 31 Europe Cancer Immunotherapy Market: By Application, 2024-2031 (Usd Million)
Figure 32 Europe Cancer Immunotherapy Market: By Application, Cagr (2024-2031)
Figure 33 Europe Cancer Immunotherapy Market: By Application, Lifeline Curve
Figure 34 Europe Cancer Immunotherapy Market: Snapshot (2023)
Figure 35 Europe Cancer Immunotherapy Market: Company Share 2023 (%)

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us